Acasti Pharma
(NASDAQ:ACST)
$2.72
0.02[0.74%]
Last update: 1:52PM Get Real Time Here
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$6.00
Lowest Price Target1
$2.40
Consensus Price Target1
$4.22

Acasti Pharma Stock (NASDAQ:ACST), Analyst Ratings, Price Targets, Predictions

Acasti Pharma Inc has a consensus price target of $4.22, established from looking at the 6 latest analyst ratings. The last 3 analyst ratings were released from Craig-Hallum, EF Hutton, and EF Hutton on February 7, 2024, February 15, 2023, and December 19, 2022. With an average price target of $3.67 between Craig-Hallum, EF Hutton, and EF Hutton, there's an implied 33.33% upside for Acasti Pharma Inc from these 3 analyst ratings.

Analyst Trend
1
Feb
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Craig-Hallum
EF Hutton
HC Wainwright & Co.
Oppenheimer

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Acasti Pharma

Buy NowGet Alert
02/07/2024Buy Now118.18%Craig-Hallum
Chase Knickerbocker
 → $6Initiates → BuyGet Alert
02/15/2023Buy Now-9.09%EF Hutton
Constantine Davides
 → $15Reiterates → BuyGet Alert
12/19/2022Buy Now-9.09%EF Hutton
Constantine Davides
 → $15Initiates → BuyGet Alert
12/15/2022Buy Now-12.73%HC Wainwright & Co.
Oren Livnat
 → $14.4Initiates → BuyGet Alert
12/22/2021Buy Now118.18%Oppenheimer
Leland Gershell
 → $36Initiates → OutperformGet Alert
12/21/2021Buy Now118.18%Oppenheimer
Leland Gershell
 → $36Initiates → OutperformGet Alert

FAQ

Q

What is the target price for Acasti Pharma (ACST)?

A

The latest price target for Acasti Pharma (NASDAQ: ACST) was reported by Craig-Hallum on February 7, 2024. The analyst firm set a price target for $6.00 expecting ACST to rise to within 12 months (a possible 120.59% upside). 1 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Acasti Pharma (ACST)?

A

The latest analyst rating for Acasti Pharma (NASDAQ: ACST) was provided by Craig-Hallum, and Acasti Pharma initiated their buy rating.

Q

When was the last upgrade for Acasti Pharma (ACST)?

A

There is no last upgrade for Acasti Pharma.

Q

When was the last downgrade for Acasti Pharma (ACST)?

A

There is no last downgrade for Acasti Pharma.

Q

When is the next analyst rating going to be posted or updated for Acasti Pharma (ACST)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acasti Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acasti Pharma was filed on February 7, 2024 so you should expect the next rating to be made available sometime around February 7, 2025.

Q

Is the Analyst Rating Acasti Pharma (ACST) correct?

A

While ratings are subjective and will change, the latest Acasti Pharma (ACST) rating was a initiated with a price target of $0.00 to $6.00. The current price Acasti Pharma (ACST) is trading at is $2.72, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.